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considerable dose to organs surrounding the target volume on top of therapeutic scatter dose. This study 
investigated the dose from a breast kilovoltage cone-beam CT (kV-CBCT), a breast megavoltage fan-
beam CT (MV-FBCT), and a TomoDirectTM breast treatment. Thermoluminescent dosimeters placed 
within a female anthropomorphic phantom were utilised to measure the dose to various organs and 
tissues. The contralateral breast, lungs and heart received 0.40 cGy, 0.45 cGy and 0.40 cGy from the kV-
CBCT and 1.74 cGy, 1.39 cGy and 1.73 cGy from the MV-FBCT. In comparison to treatment alone, daily 
imaging would increase the contralateral breast, contralateral lung and heart dose by a relative 12%, 24% 
and 13% for the kV-CBCT, and 52%, 101% and 58% for the MV-FBCT. The impact of the imaging dose 
relative to the treatment dose was assessed with linear and linear-quadratic radiation-induced secondary 
cancer risk models for the contralateral breast. The additional imaging dose and risk estimates presented 
in this study should be taken into account when considering an image modality and frequency for patient 
position verification protocols in breast radiotherapy. 
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Abstract. Imaging procedures utilised for patient position verification during breast 
radiotherapy can add a considerable dose to organs surrounding the target volume on top of 
therapeutic scatter dose. This study investigated the dose from a breast kilovoltage cone-beam 
CT (kV-CBCT), a breast megavoltage fan-beam CT (MV-FBCT), and a TomoDirectTM breast 
treatment. Thermoluminescent dosimeters placed within a female anthropomorphic phantom 
were utilised to measure the dose to various organs and tissues. The contralateral breast, lungs 
and heart received 0.40 cGy, 0.45 cGy and 0.40 cGy from the kV-CBCT and 1.74 cGy, 1.39 
cGy and 1.73 cGy from the MV-FBCT. In comparison to treatment alone, daily imaging would 
increase the contralateral breast, contralateral lung and heart dose by a relative 12%, 24% and 
13% for the kV-CBCT, and 52%, 101% and 58% for the MV-FBCT. The impact of the 
imaging dose relative to the treatment dose was assessed with linear and linear-quadratic 
radiation-induced secondary cancer risk models for the contralateral breast. The additional 
imaging dose and risk estimates presented in this study should be taken into account when 
considering an image modality and frequency for patient position verification protocols in 
breast radiotherapy.  
1.  Introduction 
Three-dimensional image guidance during breast radiotherapy is becoming more common and has 
been found to be more effective in comparison to two-dimensional image verification based on bony 
anatomy information [1]. However, these additional images will increase the dose to organs and 
tissues adjacent the treated breast, which would not receive a large dose from treatment alone. This 
may increase the likelihood of long-term side effects such as secondary cancers occurring [2]. An 
increased long-term risk of secondary cancer in the contralateral breast has been observed for breast 
radiotherapy patients who receive a dose of 1 Gy or more to the contralateral breast [2].  
This study investigated the dose to various organs and tissues from a single kV-CBCT and a single 
MV-FBCT acquired for breast patient position verification as well as a TomoDirectTM breast 
tomotherapy treatment. The risk of developing a radiation-induced secondary contralateral breast 
cancer was estimated with a general linear quadratic model [3], a linear quadratic model incorporating 
fractionation [4], and a excess relative risk model [5]. 
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2.  Materials and methods 
2.1.  Dosimetry, phantom, treatment and imaging 
The dose from a kilovoltage cone-beam CT (kV-CBCT), megavoltage fan-beam CT (MV-FBCT), and 
a 2-field TomoDirectTM breast treatment were evaluated for a female anthropomorphic phantom (CIRS 
Inc., Norfolk VA, USA). 
kV-CBCT imaging was performed on an Elekta Synergy XVI system (Elekta; Stockholm, Sweden) 
with the phantom setup on a breast board. The image protocol involved a 270° arc rotation (clockwise 
270° to 180°), with 120 kVp, 20 mA and 20 ms per frame, field-of-view size S20, no filter (F0), and 
with approximately 350 frames collected per scan. 
The breast treatment and MV-FBCT scan were performed on a Tomotherapy unit (Tomotherapy 
Inc., Madison WI, USA). The MV-FBCT was acquired with 3.5 MV photons, pitch of 8.0 (normal), 
jaw width 1 mm, and field length 15.6 cm. The TomoDirectTM treatment consisted of 2.5 cm jaw 
width, modulation factor 3.0, pitch 0.287, and beam angles 117° and 308°. 
Lithium-fluoride thermoluminescent dosimeters (TLD-100H; Harshaw, Germany), size 3.2 x 3.2 x 
0.4 mm3 were placed throughout the phantom at locations representing organs and tissues. A Harshaw 
5500 reader was utilised with a read-out cycle which included a preheat of 100°C for 10 seconds (s) 
and a linear ramp of 20°Cs-1 to 235°C for 20 s. The chips were annealed at 240 ± 2°C for 15 minutes 
and cooled rapidly on a steel block. For the kV-CBCT measurements the TLDs were calibrated with 
an orthovoltage machine (Pantak Therapax 300; Elimpex-Medizintechnik, Austria), with beam energy 
135 kVp. TLDs were calibrated on a Varian Clinac linear accelerator (Varian Medical Systems Inc., 
Palo Alto CA, USA) for the MV-FBCT and TomoDirectTM measurements. Individual chip calibration 
factors were determined and only TLD chips with a reproducibility of ± 3% were used. Dose 
measurements were repeated twice with two TLD chips at each measurement location. 
2.2.  Contralateral breast secondary cancer risk 
The risk of developing a radiation-induced cancer in the contralateral breast was estimated for 
treatment with nil imaging and treatment plus daily imaging (25 scans) for both image modalities. 
Three risk models were utilised; the UNSCEAR general linear quadratic model [3], the Dasu et al 
linear quadratic model incorporating the influence of fractionation [4], and the Preston et al excess 
relative risk (ERR) model [5]. The UNSCEAR [3] general linear quadratic model: 
𝐸𝑓𝑓𝑒𝑐𝑡 = 𝛼!𝐷 + 𝛽!𝐷! ×𝑒! !!!!!!!
!  (1) 
where D is the mean contralateral breast dose (Gy) from total treatment. The first term of the 
equation accounts for radiation-induced DNA mutations, α1 and β1 values of 0.02 Gy-1 and 0.005 Gy-2  
were utilised in this study, and the second term represents cell survival, α2 and β2 values of 0.25 Gy-1 
and 0.06 Gy-2 were utilised in this study.  
The Dasu et al [4] linear quadratic model with a fractionation parameter: 





!  (2) 
where n in the number of fractions (25 for this study). To enable comparison with the ERR model 
below, the risk values calculated above were multiplied with a factor B [6] which depends upon 
demographic and cohort factors, such that 𝐸𝑅𝑅 = 𝐵×𝐸𝑓𝑓𝑒𝑐𝑡. 
The Preston et al ERR model [5] was developed from work which examined the breast incidence 
associated with imaging and low therapeutic doses: 




where β is the ERR/Gy and γ is an exponent of attained age. The ERR model parameters were 
obtained from cohorts receiving similar dose values to those investigated in this study, this included 
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the New York acute post-partum mastitis cohort and the Massachusetts tuberculosis fluoroscopy 
cohort and its extension cohort. From this, parameters β and γ were determined to 0.68 and -1 
respectively [5]. 
3.  Results 
The dose to organs from a single breast TomoDirectTM fraction, single kV-CBCT, and a single MV-
FBCT acquired for patient position verification in breast radiotherapy are displayed in table 1. The 
cumulative dose and secondary cancer risks to the contralateral breast from treatment with nil 
imaging, treatment plus daily kV-CBCT and treatment plus daily MV-FBCT are outlined in table 2. 
Table 1: Organ doses from a single breast TomoDirectTM fraction, a single breast kV-CBCT, and a 
single breast MV-FBCT. 
Organ Dose (cGy) 
TomoDirectTM kV-CBCT MV-FBCT 
Ipsilateral breast 199.91 ± 8.32 0.51 ± 0.03 1.74 ± 0.11 
Contralateral breast 3.32 ± 0.29 0.40 ± 0.01 1.74 ± 0.11 
Ipsilateral lung 23.59 ± 2.92 0.45 ± 0.02 1.34 ± 0.15 
Contralateral lung 1.38 ± 0.07 0.33 ± 0.01 1.39 ± 0.14 
Heart 2.98 ± 0.14 0.40 ± 0.01 1.73 ± 0.08 
Table 2: The cumulative dose and excess relative risk to the contralateral breast from treatment with 
nil imaging, treatment plus daily kV-CBCT imaging and treatment plus daily MV-FBCT imaging.  
 Treatment with nil 
imaging 
Treatment plus daily 
kV-CBCT 
Treatment plus daily 
MV-FBCT 
Dose (Gy) 0.83 ± 0.07 0.99 ± 0.11 1.27 ± 0.08 
Excess relative risk    
UNSCEAR [3] 0.53 0.62 0.75 
Dasu et al [4] 0.46 0.53 0.63 
Preston et al [5]a 0.47 0.56 0.72 
aestimated for attained age 60-years, for women treated at age 50-years. A 10-year latency period for 
radiation-induced secondary malignancy is within the time period, 5-14 –years where Clarke et al [7] 
found an excess of contralateral breast cancers after breast radiotherapy. 
4.  Discussion 
For the breast patient position verification image protocols investigated in this study, the kV-CBCT 
was found to deliver a lower dose in comparison to the MV-FBCT. If utilised for daily image guidance 
the patient dose would be increased by up to a maximum 12.8 cGy for the kV-CBCT and up to 43.5 
cGy for the MV-FBCT. Patient position verification does not increase the dose to the target volume 
greatly, daily imaging increases the dose to the treated breast by a relative 0.3% and 0.9% for the kV-
CBCT and MV-FBCT respectively. However for organs surrounding the treated breast, treatment with 
daily imaging in comparison to treatment with nil imaging, increases in the contralateral breast, 
contralateral lung and heart dose by a relative 12%, 24% and 13% for the kV-CBCT and 52%, 101% 
and 58% for the MV-FBCT. For this reason, imaging dose needs to be quantified in order to assess 
potential long-term risks, such as secondary cancer. 
The significance of the imaging dose relative to the treatment dose was assessed for the 
contralateral breast with three secondary cancer risk models. The ERR estimates were similar for all 
three models, agreeing to within 9%. This is attributed to the low dose received by the contralateral 
breast for the treatment and imaging protocols. For low doses the second term in the linear quadratic 
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models [3, 4] becomes negligible and thus the risk estimates linear. The dose-risk relationship for low 
doses (less than 1 Gy) is controversial [8] however a linear-no-threshold model is generally 
recommended for low doses [3, 9, 10]. MV-FBCT daily imaging was determined to increase the ERR 
by up to a relative 53% in comparison to treatment with nil imaging. 
5.  Conclusion 
The MV-FBCT delivered a greater dose in comparison to the kV-CBCT for breast radiotherapy image 
guidance. Daily imaging was found to deliver a dose of 10.0 cGy and 12.8 cGy to the contralateral 
breast and ipsilateral breast for the kV-CBCT, and 43.5cGy and 43.5 cGy for the MV-FBCT. In 
comparison to treatment alone, the treatment plus daily imaging would increase the contralateral breast 
and ipsilateral breast dose by a relative 12% and 0.3% for the kV-CBCT, and 52% and 0.9% for the 
MV-FBCT. Thus, daily imaging increased the estimated risk of developing a radiation induced 
contralateral breast cancer relatively by up to 53% (MV-FBCT with the Preston et al ERR model). 
The dose and risk estimates presented in this study may help clinicians make informed decisions on 
the image modality type and image frequency required for patient position verification in breast 
radiotherapy. 
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